Name
RF7-04: Gedatolisib (PI3K/AKT/mTOR inhibitor) + fulvestrant ± palbociclib for 2L treatment of HR+/HER2-/PIK3CA-WT advanced breast cancer: updated VIKTORIA-1 phase 3 trial results - Commentary: Adam Brufsky, MD, PhD
Date & Time
Wednesday, December 3, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL